EP0850646A1 - Liposome preparations of indolocarbazole derivatives - Google Patents

Liposome preparations of indolocarbazole derivatives Download PDF

Info

Publication number
EP0850646A1
EP0850646A1 EP97926234A EP97926234A EP0850646A1 EP 0850646 A1 EP0850646 A1 EP 0850646A1 EP 97926234 A EP97926234 A EP 97926234A EP 97926234 A EP97926234 A EP 97926234A EP 0850646 A1 EP0850646 A1 EP 0850646A1
Authority
EP
European Patent Office
Prior art keywords
ucn
added
liposomes
liposome
liposome suspension
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP97926234A
Other languages
German (de)
French (fr)
Other versions
EP0850646B1 (en
EP0850646A4 (en
Inventor
Yasuki Kato
Masahiro Yamauchi
Kunio Ito
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KH Neochem Co Ltd
Original Assignee
Kyowa Hakko Kogyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kogyo Co Ltd filed Critical Kyowa Hakko Kogyo Co Ltd
Publication of EP0850646A1 publication Critical patent/EP0850646A1/en
Publication of EP0850646A4 publication Critical patent/EP0850646A4/en
Application granted granted Critical
Publication of EP0850646B1 publication Critical patent/EP0850646B1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings

Definitions

  • the present invention relates to a liposome preparation containing a medically useful indolocarbazole derivative.
  • UCN-01 has protein kinase C inhibitory activity [J. Antibiotics., 40 , 1782 (1987)] and has anti-tumor activity [Cancer Res., 51 , 4888 (1991)]. Further, it is disclosed in WO89/07105 that the UCN-01 derivative possesses inhibitory activity on cell growth.
  • UCN-01 or its derivative is administered in vivo particularly to blood vessels, it would be impossible to prevent UCN-01 or its derivative from contacting vascular cells and other various normal cells, as well. Because the UCN-01 derivative has inhibitory activity on cell growth, the contact of UCN-01 or its derivative with normal cells may cause certain adverse effects on normal cells.
  • the compound may undergo decomposition in blood or be accumulated in internal organs other than the target, and is thus not necessarily accumulated in tumors effectively.
  • the present invention relates to a liposome preparation characterized by encapsulating indolocarbazole derivatives represented by formula (I): (wherein R represents hydrogen or lower alkyl) into a liposome comprising lipids.
  • the lower alkyl refers to straight chain or branched chain of C1 to C6 alkyl, for example, methyl, ethyl, propyl, isopropyl, sec-butyl, tert-butyl, pentyl, hexyl, etc.
  • the indolocarbazole derivatives represented by formula (I) can be produced by the method described in Japanese Patent Application Laid-Open Publication No. 220,196/87 or WO89/07105. Specific examples of such compounds are shown in Table 1. Examples of compounds represented by formula (I) R Molecular Weight : MS (m/z) H 483 (M+1) + CH 3 497 (M+1) + C 2 H 5 510 (M) + i-C 3 H 7 524 (M) + n-C 4 H 9 538 (M) +
  • phospholipids for preparation of liposomes
  • phospholipids include natural or synthetic phospholipids such as phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, phosphatidic acid, phosphatidylgycerol, phosphatidylinositol, lysophosphatidylcholine, sphingomyelin, egg yolk lecithin and soybean lecithin, as well as hydrogenated phospholipids etc.
  • the glyceroglycolipids include sulfoxyribosyldiglyceride, diglycosyldiglyceride, digalactosyldiglyceride, galactosyldiglyceride, glycosyldiglyceride, etc.
  • the sphingoglycolipids include galactosylcerebroside, lactosylserebroside, ganglioside etc. These are used singly or in combination. If necessary, sterols such as cholesterol as membrane stabilizer, tocopherol, etc. as antioxidant, stearylamine, dicetylphosphate, ganglioside, etc. as charged substances, may be used in addition to the lipid component.
  • Modification of the surfaces of liposomes with a non-ionic surface active agent, cationic surface active agent, anionic surface active agent, polysaccharides and derivatives thereof, polyoxyethylene derivatives etc. can be carried out arbitrarily. Further modification of the surfaces of liposomes with antibodies, proteins, peptides, aliphatic acids etc. can be applied for the purpose of targeting.
  • the solution used for suspending liposomes may be an acid, alkali, various buffers, physiological saline, amino acid infusions etc. in addition to water. Further, antioxidants such as citric acid, ascorbic acid, cysteine, ethylenediaminetetraacetic acid (EDTA) etc. may also be added.
  • preservatives such as paraben, chlorobutanol, benzyl alcohol, propylene glycol etc. may also be added.
  • glycerin, glucose, sodium chloride etc. can also be added as agents for rendering the solution isotonic.
  • the known method of preparing a liposome preparation includes the liposome preparation method of Bangham et al. (J. Mol. Biol., 13 , 238 (1965)), the ethanol injection method (J. Cell. Biol., 66 , 621 (1975)), the French press method (FEBS Lett., 99 , 210 (1979)), the freezing and thawing method (Arch. Biochem. Biophys., 212 , 186 (1981)), the reverse phase evaporation method (Proc. Natl. Acad. Sci. (USA), 75 , 4194 (1978)), and the pH gradient method (Biochim. Biophys. Acta, 816 , 294 (1985); Japanese Patent Application Laid-Open Publication No. 165,560/95).
  • the pH gradient method has a large number of advantages including, for example, high encapsulation efficiency of Compound (I) in the liposome, the uniform size of the resulting liposomes, a smaller amount of the remaining organic solvent in the liposome suspension.
  • the method of preparing the liposome preparation of the present invention by use of the pH gradient method is as follows: For example, the lipids are dissolved in a solvent such as ether, ethanol etc. and then placed in an round-bottomed flask, and the solvent is evaporated to form a lipid film. Then, an acidic buffer is added to the film, followed by shaking and stirring to form larger multilamellar liposomes.
  • the liposome particles are prepared by the extrusion method etc.
  • liposomes can also be formed by dissolving Compound (I) and the lipid component in organic solvent such as ethanol etc., then evaporating the solvent off, and adding physiological saline thereto followed by shaking and stirring.
  • organic solvent such as ethanol etc.
  • the liposome preparation of the present invention obtained by e.g. the methods described above can be used as such, but can also be lyophilized after adding fillers such as mannitol, lactose, glycine etc. depending on the object of use, storage conditions etc. Lyoprotectants stabilizers such as glycerin etc. may also be added before lyophilization.
  • the liposome preparation of the present invention is used generally as an injection, but can also be used as an oral dosage form, nasal dosage form, eye drop, percutaneous dosage form, suppository, inhalation etc. by manufacturing the preparation into such forms.
  • the object of the liposome preparation of the present invention is to stabilize Compound (I) in blood and to increase its accumulation in tumors.
  • phosphatidylcholine 0.7 g was dissolved in 5 ml ether, and the solvent was evaporated under reduced pressure to form a lipid film.
  • 10 ml of 20 mM citrate buffer, pH 2.5 was added to it and shaken and stirred with a Vortex mixer. Further, this suspension was passed 5 times through 0.4 ⁇ m polycarbonate membrane filter. Further, the filtrate was passed 10 times through 0.1 ⁇ m polycarbonate membrane filter.
  • a 20 mM citrate buffer, pH 2.5 was added thereto to prepare a liposome suspension containing 50 mg/ml phosphatidylcholine.
  • a liposome suspension was prepared in the same manner as in Example 1 except that the concentration of phosphatidylcholine was made 40 mg/ml by changing the amount of 20 mM citrate buffer, pH 2.5. Separately, 200 mg of lactose, 56 mg of Na 2 HPO 4 ⁇ 12 H 2 0, and 12 mg of hydrous citric acid were added to 10 mg UCN-01, and a lyophilized product was prepared in the same manner as in Example 1. To this lyophilized product was added 2 ml of the previously prepared liposome suspension. Further, 8 ml of 200 mM Na 2 HPO 4 solution was added thereto to adjust the pH to 7.4 so that UCN-01 was encapsulated in liposomes.
  • a liposome suspension was prepared in the same manner as in Example 1 except that the concentration of phosphatidylcholine was made 30 mg/ml by changing the amount of 20 mM citrate buffer, pH 2.5. Separately, 200 mg of lactose, 56 mg of Na 2 HPO 4 ⁇ 12 H 2 0, and 12 mg of hydrous citric acid were added to 10 mg UCN-01, and a lyophilized product was prepared in the same manner as in Example 1. To this lyophilized product was added 2 ml of the previously prepared liposome suspension. Further, 8 ml of 200 mM Na 2 HPO 4 solution was added thereto to adjust the pH to 7.4 so that UCN-01 was encapsulated in liposomes.
  • a liposome suspension was prepared in the same manner as in Example 1 except that the concentration of phosphatidylcholine was made 25 mg/ml by changing the amount of 20 mM citrate buffer, pH 2.5. Separately, 200 mg of lactose, 56 mg of Na 2 HPO 4 ⁇ 12 H 2 0, and 12 mg of hydrous citric acid were added to 10 mg UCN-01, and a lyophilized product was prepared in the same manner as in Example 1. To this lyophilized product was added 2 ml of the previously prepared liposome suspension. Further, 8 ml of 200 mM Na 2 HPO 4 solution was added thereto to adjust the pH to 7.4 so that UCN-01 was encapsulated in liposomes.
  • a liposome suspension was prepared in the same manner as in Example 1 except that the concentration of phosphatidylcholine was made 25 mg/ml by changing the amount of 20 mM citrate buffer, pH 2.5. 5 mg UCN-01 was dissolved by adding 2 ml of the prepared liposome suspension. Further, 3 ml of 200 mM Na 2 HPO 4 solution was added thereto to adjust the pH to 7.4 so that UCN-01 was encapsulated in liposomes.
  • a liposome suspension was prepared in the same manner as in Example 1 except that the concentration of phosphatidylcholine was made 20 mg/ml by changing the amount of 20 mM citrate buffer, pH 2.5. 5 mg UCN-01 was dissolved by adding 2 ml of the prepared liposome suspension. Further, 3 ml of 200 mM Na 2 HPO 4 solution was added thereto to adjust the pH to 7.4 so that UCN-01 was encapsulated in liposomes.
  • a liposome suspension was prepared in the same manner as in Example 1 except that the concentration of phosphatidylcholine was made 15 mg/ml by changing the amount of 20 mM citrate buffer, pH 2.5. 5 mg UCN-01 was dissolved by adding 2 ml of the prepared liposome suspension. Further, 3 ml of 200 mM Na 2 HPO 4 solution was added thereto to adjust the pH to 7.4 so that UCN-01 was encapsulated in liposomes.
  • a liposome suspension was prepared in the same manner as in Example 1 except that the concentration of phosphatidylcholine was made 12.5 mg/ml by changing the amount of 20 mM citrate buffer, pH 2.5. 5 mg UCN-01 was dissolved by adding 2 ml of the prepared liposome suspension. Further, 3 ml of 200 mM Na 2 HPO 4 solution was added thereto to adjust the pH to 7.4 so that UCN-01 was encapsulated in liposomes.
  • Each of the UCN-01 encapsulating liposomes prepared in Examples 1 to 8 was filtered through 0.45 ⁇ m membrane filter to remove insolubles etc.
  • 1 ml of 200 mM disodium phosphate-20 mM citrate buffer, pH 7.4 was added there and the mixtures was mixed with 1ml of liposome suspension.
  • These liposomes were ultracentrifuged (110,000 ⁇ g, 1 hour) at 10 °C .
  • UCN-01 encapsulating liposome suspension prepared in the same manner as in Example 1 was introduced into a vial and sealed with a rubber stopper. Obtained samples were stored at different temperatures of 5 °C, 25 °C, and 37 °C, respectively, and the change with time of encapsulation efficiency of UCN-01 was determined. The method of determining the encapsulation efficiency was carried out in the same manner as in Test Example 1.
  • the liposome preparations of the present invention indicate high encapsulation efficiency of UCN-01.
  • Table 3 shows that the liposome preparations of the present invention are stable liposome preparations with less leakage of UCN-01.
  • phosphatidylcholine 1 g was dissolved in 5 ml ether, and the solvent was evaporated under reduced pressure to form a lipid film.
  • 10 ml of 20 mM citrate buffer, pH 4.0 was added thereto and shaken and stirred with a Vortex mixer. Further, this suspension was passed 5 times through 0.4 ⁇ m polycarbonate membrane filter. Further, the filtrate was passed 10 times through 0.1 ⁇ m polycarbonate membrane filter.
  • a 20 mM citrate buffer, pH 4.0 was added thereto to prepare a liposome suspension containing 50 mg/ml phosphatidylcholine.
  • UCN-01 was encapsulated in liposomes in the same manner as in Example 10 except that 1.2 g phosphatidylcholine and 0.3 g cholesterol were used as the starting materials of the lipid film.
  • UCN-01 was encapsulated in liposomes in the same manner as in Example 10 except that 1.2 g phosphatidylcholine, 0.4 g cholesterol and 0.4 g PEG-DSPE (1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[poly-(ethyleneglycol) 2000]; a product of AVANTI POLAR LIPIDS INCORPORATION)) were used as the starting materials of the lipid film.
  • PEG-DSPE 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[poly-(ethyleneglycol) 2000]; a product of AVANTI POLAR LIPIDS INCORPORATION
  • a liposome suspension was prepared in the same manner as in Example 10 except that the concentration of phosphatidylcholine in the liposome suspension was made 35 mg/ml by changing the amount of 20 mM citrate buffer, pH 4.0.
  • a lyophilized product of UCN-01 was prepared in the same manner as in Example 10. To this lyophilized product was added the previously prepared liposome suspension so that UCN-01 was made 0.5 mg/ml.
  • a 8 ml of 10.4 mM aqueous sodium hydroxide was added to 2 ml of this solution to adjust the pH to 8.0 so that UCN-01 was encapsulated in liposomes.
  • a liposome suspension and a lyophilized product of UCN-01 were prepared in the same manner as in Example 13. The liposome suspension was added to this lyophilized product so that UCN-01 was made 0.05 mg/ml. A 8 ml of 9.0 mM aqueous sodium hydroxide was added to 2 ml of this solution to adjust the pH to 8.0 so that UCN-01 was encapsulated in liposomes.
  • a liposome suspension and a lyophilized product of UCN-01 were prepared in the same manner as in Example 13. The liposome suspension was added to this lyophilized product so that UCN-01 was made 0.005 mg/ml. A 8 ml of 9.0 mM aqueous sodium hydroxide was added to 2 ml of this solution to adjust the pH to 8.0 so that UCN-01 was encapsulated in liposomes.
  • UCN-01 was encapsulated in liposomes in the same manner as in Example 13 except that 0.2 ⁇ m polycarbonate membrane filter was used in place of the 0.1 ⁇ m polycarbonate membrane filter to prepare a liposome suspension.
  • a liposome suspension and a lyophilized product of UCN-01 were prepared in the same manner as in Example 16. The liposome suspension was added to this lyophilized product so that UCN-01 was made 0.05 mg/ml. A 8 ml of 9.0 mM aqueous sodium hydroxide was added to 2 ml of this solution to adjust the pH to 8.0 so that UCN-01 was encapsulated in liposomes.
  • a liposome suspension and a lyophilized product of UCN-01 were prepared in the same manner as in Example 16. The liposome suspension was added to this lyophilized product so that UCN-01 was made 0.005 mg/ml. A 8 ml of 9.0 mM aqueous sodium was added to 2 ml of this solution to adjust the pH to 8.0 so that UCN-01 was encapsulated in liposomes.
  • 0.9 g phosphatidylcholine and 0.1 g phosphatidylethanolamine were evaporated in 5 ml chloroform, and the solvent was distilled off under reduced pressure whereby a lipid film was formed.
  • 10 ml of 20 mM citrate buffer, pH 4.0 was added thereto and shaken and stirred with a Vortex mixer. This suspension was passed 5 times through 0.4 ⁇ m polycarbonate membrane filter. Further, the filtrate was passed 10 times through 0.1 ⁇ m polycarbonate membrane filter. 20 mM citrate buffer, pH 4.0 was added thereto to prepare a liposome suspension containing 45 mg/ml phosphatidylcholine.
  • a lyophilized product of UCN-01 was prepared in the same manner as in Example 10. To this lyophilized product was added the previously prepared liposome suspension so that UCN-01 was made 0.5 mg/ml. A 8 ml of 10.4 mM aqueous sodium hydroxide was added to 2 ml of this solution to adjust the pH to 8.0 so that UCN-01 was encapsulated in liposomes.
  • a liposome suspension and a lyophilized product of UCN-01 were prepared in the same manner as in Example 19. The liposome suspension was added to this lyophilized product so that UCN-01 was made 0.05 mg/ml. A 8 ml of 9.0 mM aqueous sodium hydroxide was added to 2 ml of this solution to adjust the pH to 8.0 so that UCN-01 was encapsulated in liposomes.
  • a liposome suspension and a lyophilized product of UCN-01 were prepared in the same manner as in Example 19. The liposome suspension was added to this lyophilized product so that UCN-01 was made 0.005 mg/ml. A 8 ml of 9.0 mM aqueous sodium hydroxide was added to 2 ml of this solution to adjust the pH to 8.0 so that UCN-01 was encapsulated in liposomes.
  • lipid film was formed.
  • 10 ml of 20 mM citrate buffer, pH 4.0 was added thereto and shaken and stirred with a Vortex mixer. This suspension was passed 5 times through 0.4 ⁇ m polycarbonate membrane filter. Further, the filtrate was passed 10 times through 0.1 ⁇ m polycarbonate membrane filter.
  • a 20 mM citrate buffer, pH 4.0 was added thereto to prepare a liposome suspension containing 35 mg/ml phosphatidylcholine.
  • a lyophilized product of UCN-01 was prepared in the same manner as in Example 10. To this lyophilized product was added the previously prepared liposome suspension so that UCN-01 was made 0.5 mg/ml. 8 ml of 10.4 mM aqueous sodium hydroxide was added to 2 ml of this solution to adjust the pH to 8.0 so that UCN-01 was encapsulated in liposomes.
  • a liposome suspension and a lyophilized product of UCN-01 were prepared in the same manner as in Example 22.
  • the liposome suspension was added to this lyophilized product such that UCN-01 was made 0.05 mg/ml.
  • a 8 ml of 9.0 mM aqueous sodium hydroxide was added to 2 ml of this solution to adjust the pH to 8.0 so that UCN-01 was encapsulated in liposomes.
  • a liposome suspension and a lyophilized product of UCN-01 were prepared in the same manner as in Example 22.
  • the liposome suspension was added to this lyophilized product so that UCN-01 was made 0.005 mg/ml.
  • a 8 ml of 9.0 mM aqueous sodium hydroxide was added to 2 ml of this solution to adjust the pH to 8.0 so that UCN-01 was encapsulated in liposomes.
  • UCN-01 was encapsulated in liposomes in the same manner as in Example 22 except that 0.7 g phosphatidylcholine and 0.3 g cholesterol were used as the starting materials of the lipid film.
  • a liposome suspension and a lyophilized product of UCN-01 were prepared in the same manner as in Example 25.
  • the liposome suspension was added to this lyophilized product so that UCN-01 was made 0.05 mg/ml.
  • a 8 ml of 9.0 mM aqueous sodium hydroxide was added to 2 ml of this solution to adjust the pH to 8.0 so that UCN-01 was encapsulated in liposomes.
  • a liposome suspension and a lyophilized product of UCN-01 were prepared in the same manner as in Example 25.
  • the liposome suspension was added to this lyophilized product so that UCN-01 was made 0.005 mg/ml.
  • a 8 ml of 9.0 mM aqueous sodium hydroxide was added to 2 ml of this solution to adjust the pH to 8.0 so that UCN-01 was encapsulated in liposomes.
  • a liposome preparation in which a medically useful indolocarbazole derivative has been included.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention provides a liposome preparation characterized by encapsulating indolocarbazole derivatives represented by formula (I):

Description

TECHNICAL FIELD
The present invention relates to a liposome preparation containing a medically useful indolocarbazole derivative.
BACKGROUND ART
Figure 00010001
It is known that UCN-01 has protein kinase C inhibitory activity [J. Antibiotics., 40, 1782 (1987)] and has anti-tumor activity [Cancer Res., 51, 4888 (1991)]. Further, it is disclosed in WO89/07105 that the UCN-01 derivative possesses inhibitory activity on cell growth.
In case UCN-01 or its derivative is administered in vivo particularly to blood vessels, it would be impossible to prevent UCN-01 or its derivative from contacting vascular cells and other various normal cells, as well. Because the UCN-01 derivative has inhibitory activity on cell growth, the contact of UCN-01 or its derivative with normal cells may cause certain adverse effects on normal cells.
In case UCN-01 or its derivative is administered as such to blood vessels, the compound may undergo decomposition in blood or be accumulated in internal organs other than the target, and is thus not necessarily accumulated in tumors effectively.
There is demand for a preparation containing UCN-01 or its derivative, which is stabilized in blood and accumulated at high levels in tumors without causing any effect on normal cells.
DISCLOSURE OF THE INVENTION
The present invention relates to a liposome preparation characterized by encapsulating indolocarbazole derivatives represented by formula (I):
Figure 00020001
(wherein R represents hydrogen or lower alkyl) into a liposome comprising lipids.
Hereinafter, the compound represented by formula (I) is referred to as Compound (I).
In the definition for the formula of Compound (I), the lower alkyl refers to straight chain or branched chain of C1 to C6 alkyl, for example, methyl, ethyl, propyl, isopropyl, sec-butyl, tert-butyl, pentyl, hexyl, etc.
The indolocarbazole derivatives represented by formula (I) can be produced by the method described in Japanese Patent Application Laid-Open Publication No. 220,196/87 or WO89/07105. Specific examples of such compounds are shown in Table 1.
Figure 00040001
Examples of compounds represented by formula (I)
R Molecular Weight : MS (m/z)
H 483 (M+1)+
CH3 497 (M+1)+
C2H5 510 (M)+
i-C3H7 524 (M)+
n-C4H9 538 (M)+
As the lipids for preparation of liposomes, mention is made of phospholipids, glyceroglycolipids, and sphingoglycolipids among which phospholipids are preferably used. Examples of such phospholipids include natural or synthetic phospholipids such as phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, phosphatidic acid, phosphatidylgycerol, phosphatidylinositol, lysophosphatidylcholine, sphingomyelin, egg yolk lecithin and soybean lecithin, as well as hydrogenated phospholipids etc.
The glyceroglycolipids include sulfoxyribosyldiglyceride, diglycosyldiglyceride, digalactosyldiglyceride, galactosyldiglyceride, glycosyldiglyceride, etc.
The sphingoglycolipids include galactosylcerebroside, lactosylserebroside, ganglioside etc. These are used singly or in combination. If necessary, sterols such as cholesterol as membrane stabilizer, tocopherol, etc. as antioxidant, stearylamine, dicetylphosphate, ganglioside, etc. as charged substances, may be used in addition to the lipid component.
Modification of the surfaces of liposomes with a non-ionic surface active agent, cationic surface active agent, anionic surface active agent, polysaccharides and derivatives thereof, polyoxyethylene derivatives etc. can be carried out arbitrarily. Further modification of the surfaces of liposomes with antibodies, proteins, peptides, aliphatic acids etc. can be applied for the purpose of targeting. The solution used for suspending liposomes may be an acid, alkali, various buffers, physiological saline, amino acid infusions etc. in addition to water. Further, antioxidants such as citric acid, ascorbic acid, cysteine, ethylenediaminetetraacetic acid (EDTA) etc. may also be added. Furthermore, preservatives such as paraben, chlorobutanol, benzyl alcohol, propylene glycol etc. may also be added. In addition, glycerin, glucose, sodium chloride etc. can also be added as agents for rendering the solution isotonic.
For production of the liposome preparation of the present invention, a method of preparing a known liposome preparation can be used. The known method of preparing a liposome preparation includes the liposome preparation method of Bangham et al. (J. Mol. Biol., 13, 238 (1965)), the ethanol injection method (J. Cell. Biol., 66, 621 (1975)), the French press method (FEBS Lett., 99, 210 (1979)), the freezing and thawing method (Arch. Biochem. Biophys., 212, 186 (1981)), the reverse phase evaporation method (Proc. Natl. Acad. Sci. (USA), 75, 4194 (1978)), and the pH gradient method (Biochim. Biophys. Acta, 816, 294 (1985); Japanese Patent Application Laid-Open Publication No. 165,560/95).
Among these methods, the pH gradient method has a large number of advantages including, for example, high encapsulation efficiency of Compound (I) in the liposome, the uniform size of the resulting liposomes, a smaller amount of the remaining organic solvent in the liposome suspension. The method of preparing the liposome preparation of the present invention by use of the pH gradient method is as follows: For example, the lipids are dissolved in a solvent such as ether, ethanol etc. and then placed in an round-bottomed flask, and the solvent is evaporated to form a lipid film. Then, an acidic buffer is added to the film, followed by shaking and stirring to form larger multilamellar liposomes. The liposome particles are prepared by the extrusion method etc. so that their average particle diameter is made e.g. about 100 nm. After a weakly acidic solution of Compound (I) is added to this liposome suspension, a suitable buffer is added so that the pH of the liposome suspension is raised at about neutrality (the difference between the pH values of the liposome suspension before and after the rise of pH is preferably 3 or more). By the above operation, Compound (I) can be encapsulated in the inside of the liposomes.
Alternatively, liposomes can also be formed by dissolving Compound (I) and the lipid component in organic solvent such as ethanol etc., then evaporating the solvent off, and adding physiological saline thereto followed by shaking and stirring.
The liposome preparation of the present invention obtained by e.g. the methods described above can be used as such, but can also be lyophilized after adding fillers such as mannitol, lactose, glycine etc. depending on the object of use, storage conditions etc. Lyoprotectants stabilizers such as glycerin etc. may also be added before lyophilization.
The liposome preparation of the present invention is used generally as an injection, but can also be used as an oral dosage form, nasal dosage form, eye drop, percutaneous dosage form, suppository, inhalation etc. by manufacturing the preparation into such forms.
Hereinafter, the Examples and Test Examples of the present invention are shown.
The object of the liposome preparation of the present invention is to stabilize Compound (I) in blood and to increase its accumulation in tumors.
BEST MODE FOR CARRYING OUT THE INVENTION Example 1
phosphatidylcholine 0.7 g was dissolved in 5 ml ether, and the solvent was evaporated under reduced pressure to form a lipid film. 10 ml of 20 mM citrate buffer, pH 2.5 was added to it and shaken and stirred with a Vortex mixer. Further, this suspension was passed 5 times through 0.4 µm polycarbonate membrane filter. Further, the filtrate was passed 10 times through 0.1 µm polycarbonate membrane filter. A 20 mM citrate buffer, pH 2.5 was added thereto to prepare a liposome suspension containing 50 mg/ml phosphatidylcholine. Separately, 200 mg lactose, 56 mg Na2HPO4·12 H20 and 12 mg hydrous citric acid were added to 10 mg UCN-01, and the mixture was dissolved in a distilled water to give 10 ml solution which was then introduced into a glass vial and lyophilized. After lyophilization, the glass vial was returned to normal pressure under a nitrogen stream and sealed to give a lyophilized product of UCN-01 in it. To this lyophilized product was added 2 ml of the previously prepared liposome suspension. Further, 8 ml of 200 mM Na2HPO4 solution disodium phosphate was added thereto to adjust the pH to 7.4 so that UCN-01 was encapsulated in liposomes.
Example 2
A liposome suspension was prepared in the same manner as in Example 1 except that the concentration of phosphatidylcholine was made 40 mg/ml by changing the amount of 20 mM citrate buffer, pH 2.5. Separately, 200 mg of lactose, 56 mg of Na2HPO4·12 H20, and 12 mg of hydrous citric acid were added to 10 mg UCN-01, and a lyophilized product was prepared in the same manner as in Example 1. To this lyophilized product was added 2 ml of the previously prepared liposome suspension. Further, 8 ml of 200 mM Na2HPO4 solution was added thereto to adjust the pH to 7.4 so that UCN-01 was encapsulated in liposomes.
Example 3
A liposome suspension was prepared in the same manner as in Example 1 except that the concentration of phosphatidylcholine was made 30 mg/ml by changing the amount of 20 mM citrate buffer, pH 2.5. Separately, 200 mg of lactose, 56 mg of Na2HPO4·12 H20, and 12 mg of hydrous citric acid were added to 10 mg UCN-01, and a lyophilized product was prepared in the same manner as in Example 1. To this lyophilized product was added 2 ml of the previously prepared liposome suspension. Further, 8 ml of 200 mM Na2HPO4 solution was added thereto to adjust the pH to 7.4 so that UCN-01 was encapsulated in liposomes.
Example 4
A liposome suspension was prepared in the same manner as in Example 1 except that the concentration of phosphatidylcholine was made 25 mg/ml by changing the amount of 20 mM citrate buffer, pH 2.5. Separately, 200 mg of lactose, 56 mg of Na2HPO4·12 H20, and 12 mg of hydrous citric acid were added to 10 mg UCN-01, and a lyophilized product was prepared in the same manner as in Example 1. To this lyophilized product was added 2 ml of the previously prepared liposome suspension. Further, 8 ml of 200 mM Na2HPO4 solution was added thereto to adjust the pH to 7.4 so that UCN-01 was encapsulated in liposomes.
Example 5
A liposome suspension was prepared in the same manner as in Example 1 except that the concentration of phosphatidylcholine was made 25 mg/ml by changing the amount of 20 mM citrate buffer, pH 2.5. 5 mg UCN-01 was dissolved by adding 2 ml of the prepared liposome suspension. Further, 3 ml of 200 mM Na2HPO4 solution was added thereto to adjust the pH to 7.4 so that UCN-01 was encapsulated in liposomes.
Example 6
A liposome suspension was prepared in the same manner as in Example 1 except that the concentration of phosphatidylcholine was made 20 mg/ml by changing the amount of 20 mM citrate buffer, pH 2.5. 5 mg UCN-01 was dissolved by adding 2 ml of the prepared liposome suspension. Further, 3 ml of 200 mM Na2HPO4 solution was added thereto to adjust the pH to 7.4 so that UCN-01 was encapsulated in liposomes.
Example 7
A liposome suspension was prepared in the same manner as in Example 1 except that the concentration of phosphatidylcholine was made 15 mg/ml by changing the amount of 20 mM citrate buffer, pH 2.5. 5 mg UCN-01 was dissolved by adding 2 ml of the prepared liposome suspension. Further, 3 ml of 200 mM Na2HPO4 solution was added thereto to adjust the pH to 7.4 so that UCN-01 was encapsulated in liposomes.
Example 8
A liposome suspension was prepared in the same manner as in Example 1 except that the concentration of phosphatidylcholine was made 12.5 mg/ml by changing the amount of 20 mM citrate buffer, pH 2.5. 5 mg UCN-01 was dissolved by adding 2 ml of the prepared liposome suspension. Further, 3 ml of 200 mM Na2HPO4 solution was added thereto to adjust the pH to 7.4 so that UCN-01 was encapsulated in liposomes.
Example 9
5 mg UCN-01 and 100 mg phosphatidylcholine were dissolved in 15 ml ethanol. The solvent was evaporated under reduced pressure whereby a lipid film was formed. 1 ml of 5 weight-% glucose was added thereto and shaken and stirred with a Vortex mixer. This liposome suspension was passed 4 times through 0.4 µm polycarbonate membrane filter. Further, the filtrate was passed 10 times through 0.1 µm polycarbonate membrane filter so that UCN-01 was encapsulated in liposomes.
Test Example 1
Each of the UCN-01 encapsulating liposomes prepared in Examples 1 to 8 was filtered through 0.45 µm membrane filter to remove insolubles etc. In the case of the liposomes of Examples 1 to 4, 1 ml of 200 mM disodium phosphate-20 mM citrate buffer, pH 7.4 was added there and the mixtures was mixed with 1ml of liposome suspension. These liposomes were ultracentrifuged (110,000 × g, 1 hour) at 10 °C . The phospholipid before and after filtration, and the phospholipid in the supernatant after ultracentrifugation, were quantified by the enzyme method [Practical Clinical Chemistry (enlarged edition), 580 (1982)] using Determiner PL (KYOWA MEDEX CO., LTD.). In addition, UCN-01 before and after filtration, and UCN-01 in the supernatant after ultracentrifugation, were quantified by high performance liquid chromatography. The encapsulation efficiency was calculated by the following formula. Encapsulation efficiency (%) = [(A - B)/(C - D)] / (E/F) × 100
  • A: Concentration of UCN-01 in the filtrate after filtration (mg/ml)
  • B: Concentration of UCN-01 in the supernatant after ultracentrifugation (mg/ml)
  • C: Concentration of the phospholipid in the filtrate after filtration (mg/ml)
  • D: Concentration of the phospholipid in the ultracentrifuged supernatant (mg/ml)
  • E: Concentration of UCN-01 in the suspension before filtration (mg/ml)
  • F: Concentration of the phospholipid in the suspension before filtration (mg/ml)
    • Analytical Conditions for High Performance Liquid Chromatography
  • Column: Capsule pack PAK C18 UG120 (SHISEID Co., Ltd.) S-5, 4.6 mm × 250 mm
  • Mobile phase: 20 mM Tris-HCl buffer, pH 9.0 : acetonitrile : tetrahydrofuran = 60 : 22 : 18 (parts by volume).
  • Flow rate: 0.8 ml/min.
  • Column temperature: 25 °C.
  • Detection wavelength: 285 nm.
    • The results are shown in Table 2.
    Encapsulation efficiency of UCN-01
    Sample Encapsulation efficiency of UCN-01 (%)
    Example 1 108.3
    Example 2 98.1
    Example 3 81.8
    Example 4 68.4
    Example 5 101.6
    Example 6 91.8
    Example 7 78.7
    Example 8 56.8
    Test Example 2
    To determine the leakage of UCN-01 from liposomes, a UCN-01 encapsulating liposome suspension prepared in the same manner as in Example 1 was introduced into a vial and sealed with a rubber stopper. Obtained samples were stored at different temperatures of 5 °C, 25 °C, and 37 °C, respectively, and the change with time of encapsulation efficiency of UCN-01 was determined. The method of determining the encapsulation efficiency was carried out in the same manner as in Test Example 1.
    The results are shown in Table 3.
    Change with Time of Encapsulation efficiency of Inclusion of UCN-01
    Time Encapsulation efficiency (%)
    5 °C 25 °C 37 °C
    0 108.2 108.2 108.2
    1 93.0 99.3 102.8
    3 114.9 96.2 101.5
    6 99.2 95.1 100.8
    24 93.2 96.5 88.6
    As can be seen from Table 2, the liposome preparations of the present invention indicate high encapsulation efficiency of UCN-01. In addition, Table 3 shows that the liposome preparations of the present invention are stable liposome preparations with less leakage of UCN-01.
    Example 10
    1 g phosphatidylcholine was dissolved in 5 ml ether, and the solvent was evaporated under reduced pressure to form a lipid film. 10 ml of 20 mM citrate buffer, pH 4.0 was added thereto and shaken and stirred with a Vortex mixer. Further, this suspension was passed 5 times through 0.4 µm polycarbonate membrane filter. Further, the filtrate was passed 10 times through 0.1 µm polycarbonate membrane filter. A 20 mM citrate buffer, pH 4.0 was added thereto to prepare a liposome suspension containing 50 mg/ml phosphatidylcholine. Separately, 200 mg lactose, 56 mg Na2HPO4·12 H20 and 12 mg hydrous citric acid were added to 10 mg UCN-01, and its lyophilized product was prepared in the same manner as in Example 1. To this lyophilized product was added 2 ml of the previously prepared liposome suspension. Further, 8 ml of 28.2 mM aqueous sodium hydroxide was added thereto to adjust the pH to 8.0 so that UCN-01 was included in liposomes.
    Example 11
    UCN-01 was encapsulated in liposomes in the same manner as in Example 10 except that 1.2 g phosphatidylcholine and 0.3 g cholesterol were used as the starting materials of the lipid film.
    Example 12
    UCN-01 was encapsulated in liposomes in the same manner as in Example 10 except that 1.2 g phosphatidylcholine, 0.4 g cholesterol and 0.4 g PEG-DSPE (1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[poly-(ethyleneglycol) 2000]; a product of AVANTI POLAR LIPIDS INCORPORATION)) were used as the starting materials of the lipid film.
    Example 13
    A liposome suspension was prepared in the same manner as in Example 10 except that the concentration of phosphatidylcholine in the liposome suspension was made 35 mg/ml by changing the amount of 20 mM citrate buffer, pH 4.0. Separately, a lyophilized product of UCN-01 was prepared in the same manner as in Example 10. To this lyophilized product was added the previously prepared liposome suspension so that UCN-01 was made 0.5 mg/ml. A 8 ml of 10.4 mM aqueous sodium hydroxide was added to 2 ml of this solution to adjust the pH to 8.0 so that UCN-01 was encapsulated in liposomes.
    Example 14
    A liposome suspension and a lyophilized product of UCN-01 were prepared in the same manner as in Example 13. The liposome suspension was added to this lyophilized product so that UCN-01 was made 0.05 mg/ml. A 8 ml of 9.0 mM aqueous sodium hydroxide was added to 2 ml of this solution to adjust the pH to 8.0 so that UCN-01 was encapsulated in liposomes.
    Example 15
    A liposome suspension and a lyophilized product of UCN-01 were prepared in the same manner as in Example 13. The liposome suspension was added to this lyophilized product so that UCN-01 was made 0.005 mg/ml. A 8 ml of 9.0 mM aqueous sodium hydroxide was added to 2 ml of this solution to adjust the pH to 8.0 so that UCN-01 was encapsulated in liposomes.
    Example 16
    UCN-01 was encapsulated in liposomes in the same manner as in Example 13 except that 0.2 µm polycarbonate membrane filter was used in place of the 0.1 µm polycarbonate membrane filter to prepare a liposome suspension.
    Example 17
    A liposome suspension and a lyophilized product of UCN-01 were prepared in the same manner as in Example 16. The liposome suspension was added to this lyophilized product so that UCN-01 was made 0.05 mg/ml. A 8 ml of 9.0 mM aqueous sodium hydroxide was added to 2 ml of this solution to adjust the pH to 8.0 so that UCN-01 was encapsulated in liposomes.
    Example 18
    A liposome suspension and a lyophilized product of UCN-01 were prepared in the same manner as in Example 16. The liposome suspension was added to this lyophilized product so that UCN-01 was made 0.005 mg/ml. A 8 ml of 9.0 mM aqueous sodium was added to 2 ml of this solution to adjust the pH to 8.0 so that UCN-01 was encapsulated in liposomes.
    Example 19
    0.9 g phosphatidylcholine and 0.1 g phosphatidylethanolamine were evaporated in 5 ml chloroform, and the solvent was distilled off under reduced pressure whereby a lipid film was formed. 10 ml of 20 mM citrate buffer, pH 4.0 was added thereto and shaken and stirred with a Vortex mixer. This suspension was passed 5 times through 0.4 µm polycarbonate membrane filter. Further, the filtrate was passed 10 times through 0.1 µm polycarbonate membrane filter. 20 mM citrate buffer, pH 4.0 was added thereto to prepare a liposome suspension containing 45 mg/ml phosphatidylcholine. Separately, a lyophilized product of UCN-01 was prepared in the same manner as in Example 10. To this lyophilized product was added the previously prepared liposome suspension so that UCN-01 was made 0.5 mg/ml. A 8 ml of 10.4 mM aqueous sodium hydroxide was added to 2 ml of this solution to adjust the pH to 8.0 so that UCN-01 was encapsulated in liposomes.
    Example 20
    A liposome suspension and a lyophilized product of UCN-01 were prepared in the same manner as in Example 19. The liposome suspension was added to this lyophilized product so that UCN-01 was made 0.05 mg/ml. A 8 ml of 9.0 mM aqueous sodium hydroxide was added to 2 ml of this solution to adjust the pH to 8.0 so that UCN-01 was encapsulated in liposomes.
    Example 21
    A liposome suspension and a lyophilized product of UCN-01 were prepared in the same manner as in Example 19. The liposome suspension was added to this lyophilized product so that UCN-01 was made 0.005 mg/ml. A 8 ml of 9.0 mM aqueous sodium hydroxide was added to 2 ml of this solution to adjust the pH to 8.0 so that UCN-01 was encapsulated in liposomes.
    Example 22
    0.7 g phosphatidylcholine and 0.3 g phosphatidylgycerol were dissolved in 5 ml chloroform, and the solvent was evaporated under reduced pressure whereby a lipid film was formed. 10 ml of 20 mM citrate buffer, pH 4.0 was added thereto and shaken and stirred with a Vortex mixer. This suspension was passed 5 times through 0.4 µm polycarbonate membrane filter. Further, the filtrate was passed 10 times through 0.1 µm polycarbonate membrane filter. A 20 mM citrate buffer, pH 4.0 was added thereto to prepare a liposome suspension containing 35 mg/ml phosphatidylcholine. Separately, a lyophilized product of UCN-01 was prepared in the same manner as in Example 10. To this lyophilized product was added the previously prepared liposome suspension so that UCN-01 was made 0.5 mg/ml. 8 ml of 10.4 mM aqueous sodium hydroxide was added to 2 ml of this solution to adjust the pH to 8.0 so that UCN-01 was encapsulated in liposomes.
    Example 23
    A liposome suspension and a lyophilized product of UCN-01 were prepared in the same manner as in Example 22. The liposome suspension was added to this lyophilized product such that UCN-01 was made 0.05 mg/ml. A 8 ml of 9.0 mM aqueous sodium hydroxide was added to 2 ml of this solution to adjust the pH to 8.0 so that UCN-01 was encapsulated in liposomes.
    Example 24
    A liposome suspension and a lyophilized product of UCN-01 were prepared in the same manner as in Example 22. The liposome suspension was added to this lyophilized product so that UCN-01 was made 0.005 mg/ml. A 8 ml of 9.0 mM aqueous sodium hydroxide was added to 2 ml of this solution to adjust the pH to 8.0 so that UCN-01 was encapsulated in liposomes.
    Example 25
    UCN-01 was encapsulated in liposomes in the same manner as in Example 22 except that 0.7 g phosphatidylcholine and 0.3 g cholesterol were used as the starting materials of the lipid film.
    Example 26
    A liposome suspension and a lyophilized product of UCN-01 were prepared in the same manner as in Example 25. The liposome suspension was added to this lyophilized product so that UCN-01 was made 0.05 mg/ml. A 8 ml of 9.0 mM aqueous sodium hydroxide was added to 2 ml of this solution to adjust the pH to 8.0 so that UCN-01 was encapsulated in liposomes.
    Example 27
    A liposome suspension and a lyophilized product of UCN-01 were prepared in the same manner as in Example 25. The liposome suspension was added to this lyophilized product so that UCN-01 was made 0.005 mg/ml. A 8 ml of 9.0 mM aqueous sodium hydroxide was added to 2 ml of this solution to adjust the pH to 8.0 so that UCN-01 was encapsulated in liposomes.
    Test Example 3
    The UCN-01 encapsulating liposomes prepared in Examples 10 to 12 were treated in the same manner as in Test Example 1 and the encapsulation efficiency of UCN-01 in each liposome was examined. The results are shown in Table 4.
    Encapsulation efficiency of UCN-01 (%)
    Sample Encapsulation efficiency of UCN-01 (%)
    Example 10 100.0
    Example 11 85.7
    Example 12 82.9
    Test Example 4
    The UCN-01 encapsulating liposomes prepared in Examples 13 to 27 were ultracentrifuged (110,000 × g, 2 hours) at 10 °C. UCN-01 before ultracentrifugation, and UCN-01 in the supernatant after ultracentrifugation, were quantified by high performance liquid chromatography. The encapsulation efficiency was calculated by the following formula: Encapsulation efficiency of UCN-01 (%) = (B - A) × 100/B
  • A: Concentration of UCN-01 in the ultracentrifuged supernatant (mg/ml)
  • B: Concentration of UCN-01 in the suspension before ultracentrifugation (mg/ml)
    • Analytical Conditions for High Performance Liquid Chromatography
  • Column: YMC AM-312, 6.00 mm diameter × 150 mm length (manufactured by YMC Co., Ltd.).
  • Mobile phase: 0.05 M phosphate buffer (plus 0.1 % triethylamine), pH 7.3 : acetonitrile = 1 : 1 (part by volume).
  • Flow rate: 1.0 ml/min.
  • Column temperature: 25 °C.
  • Detection: Excitation wavelength 310 nm, Emission wavelength 410 nm.
    • The results are shown in Table 5.
    Encapsulation efficiency of UCN-01
    Sample Encapsulation efficiency of UCN-01 (%)
    Example 13 98.7
    Example 14 99.0
    Example 15 96.8
    Example 16 99.2
    Example 17 99.2
    Example 18 94.0
    Example 19 99.9
    Example 20 99.7
    Example 21 88.5
    Example 22 98.9
    Example 23 99.4
    Example 24 100.0
    Example 25 99.6
    Example 26 99.4
    Example 27 92.0
    INDUSTRIAL APPLICABILITY
    According to the present invention, there is provided a liposome preparation in which a medically useful indolocarbazole derivative has been included.

    Claims (2)

    1. A liposome preparation characterized by encapsulating indolocarbazole derivatives represented by formula (I):
      Figure 00240001
      (wherein R represents hydrogen or lower alkyl) into a liposome comprising lipids.
    2. A liposome preparation according to claim 1 wherein lipids is phospholipids.
    EP97926234A 1996-06-18 1997-06-12 Liposome preparations of indolocarbazole derivatives Expired - Lifetime EP0850646B1 (en)

    Applications Claiming Priority (3)

    Application Number Priority Date Filing Date Title
    JP156459/96 1996-06-18
    JP15645996 1996-06-18
    PCT/JP1997/002033 WO1997048398A1 (en) 1996-06-18 1997-06-12 Liposome preparations of indolocarbazole derivatives

    Publications (3)

    Publication Number Publication Date
    EP0850646A1 true EP0850646A1 (en) 1998-07-01
    EP0850646A4 EP0850646A4 (en) 2005-06-22
    EP0850646B1 EP0850646B1 (en) 2007-12-26

    Family

    ID=15628218

    Family Applications (1)

    Application Number Title Priority Date Filing Date
    EP97926234A Expired - Lifetime EP0850646B1 (en) 1996-06-18 1997-06-12 Liposome preparations of indolocarbazole derivatives

    Country Status (10)

    Country Link
    US (1) US6045822A (en)
    EP (1) EP0850646B1 (en)
    AT (1) ATE381932T1 (en)
    AU (1) AU718856B2 (en)
    CA (1) CA2229892C (en)
    DE (1) DE69738416T2 (en)
    DK (1) DK0850646T3 (en)
    ES (1) ES2296311T3 (en)
    PT (1) PT850646E (en)
    WO (1) WO1997048398A1 (en)

    Cited By (3)

    * Cited by examiner, † Cited by third party
    Publication number Priority date Publication date Assignee Title
    WO2001000173A1 (en) * 1999-06-24 2001-01-04 Kyowa Hakko Kogyo Co., Ltd. Method of regulating leakage of drug encapsulated in liposomes
    EP1102758A1 (en) * 1998-08-06 2001-05-30 Cephalon, Inc. Particle-forming compositions containing fused pyrrolocarbazoles
    US7795246B2 (en) 1998-08-06 2010-09-14 Cephalon, Inc. Particle-forming compositions containing fused pyrrolocarbazoles

    Families Citing this family (6)

    * Cited by examiner, † Cited by third party
    Publication number Priority date Publication date Assignee Title
    DK1347743T3 (en) * 2000-12-07 2006-07-03 Univ Utrecht Holding Bv Preparation for the treatment of inflammatory disorders
    US7396852B2 (en) 2005-11-16 2008-07-08 Xerox Corporation Compound having indolocarbazole moiety and divalent linkage
    US20060124921A1 (en) * 2004-12-14 2006-06-15 Xerox Corporation Compound with indolocarbazole moieties and devices containing such compound
    TWI468188B (en) 2008-01-30 2015-01-11 Univ Tokushima Anti-cancer effect enhancers consisting of oxaliplatin liposomal preparations and anticancer agents comprising the formulation
    JP5638204B2 (en) * 2009-05-29 2014-12-10 国立大学法人 岡山大学 Liposome preparation for oral administration and production method thereof
    SG10201701063WA (en) 2012-08-10 2017-04-27 Taiho Pharmaceutical Co Ltd Stable oxaliplatin-encapsulating liposome aqueous dispersion and method for stabilizing same

    Citations (2)

    * Cited by examiner, † Cited by third party
    Publication number Priority date Publication date Assignee Title
    EP0383919A1 (en) * 1988-02-04 1990-08-29 Kyowa Hakko Kogyo Co., Ltd. Staurosporin derivatives
    EP0711557A1 (en) * 1994-11-09 1996-05-15 Ciba-Geigy Ag Base for formulating pharmaceutical agents

    Family Cites Families (4)

    * Cited by examiner, † Cited by third party
    Publication number Priority date Publication date Assignee Title
    US4952567A (en) * 1988-05-09 1990-08-28 City Of Hope Inhibition of lipogenesis
    JP2694701B2 (en) * 1989-08-24 1997-12-24 日本油脂株式会社 Liquid film cancer drug
    IL100833A0 (en) * 1991-02-20 1992-09-06 Greenwich Pharma Method for synthesis of ethereally substituted blocked monosaccharides
    JPH07278016A (en) * 1994-04-13 1995-10-24 Pola Chem Ind Inc Anticancer agent liposome pharmaceutical preparation

    Patent Citations (2)

    * Cited by examiner, † Cited by third party
    Publication number Priority date Publication date Assignee Title
    EP0383919A1 (en) * 1988-02-04 1990-08-29 Kyowa Hakko Kogyo Co., Ltd. Staurosporin derivatives
    EP0711557A1 (en) * 1994-11-09 1996-05-15 Ciba-Geigy Ag Base for formulating pharmaceutical agents

    Non-Patent Citations (2)

    * Cited by examiner, † Cited by third party
    Title
    See also references of WO9748398A1 *
    TSCHAIKOWSKY K: "Protein kinase C inhibitors suppress LPS-induced TNF production in alveolar macrophages and in whole blood: the role of encapsulation into liposomes." BIOCHIMICA ET BIOPHYSICA ACTA. 26 MAY 1994, vol. 1222, no. 1, 26 May 1994 (1994-05-26), pages 113-121, XP002325959 ISSN: 0006-3002 *

    Cited By (7)

    * Cited by examiner, † Cited by third party
    Publication number Priority date Publication date Assignee Title
    EP1102758A1 (en) * 1998-08-06 2001-05-30 Cephalon, Inc. Particle-forming compositions containing fused pyrrolocarbazoles
    EP1102758A4 (en) * 1998-08-06 2002-07-24 Cephalon Inc Particle-forming compositions containing fused pyrrolocarbazoles
    US6660729B1 (en) 1998-08-06 2003-12-09 Cephalon, Inc. Particle-forming compositions containing fused pyrrolocarbazoles
    US7795246B2 (en) 1998-08-06 2010-09-14 Cephalon, Inc. Particle-forming compositions containing fused pyrrolocarbazoles
    WO2001000173A1 (en) * 1999-06-24 2001-01-04 Kyowa Hakko Kogyo Co., Ltd. Method of regulating leakage of drug encapsulated in liposomes
    EP1190705A1 (en) * 1999-06-24 2002-03-27 Kyowa Hakko Kogyo Co., Ltd. Method of regulating leakage of drug encapsulated in liposomes
    EP1190705A4 (en) * 1999-06-24 2009-03-18 Kyowa Hakko Kogyo Kk Method of regulating leakage of drug encapsulated in liposomes

    Also Published As

    Publication number Publication date
    WO1997048398A1 (en) 1997-12-24
    PT850646E (en) 2008-03-31
    CA2229892C (en) 2003-01-07
    AU3106697A (en) 1998-01-07
    EP0850646B1 (en) 2007-12-26
    ATE381932T1 (en) 2008-01-15
    CA2229892A1 (en) 1997-12-24
    DE69738416T2 (en) 2008-12-11
    EP0850646A4 (en) 2005-06-22
    DE69738416D1 (en) 2008-02-07
    US6045822A (en) 2000-04-04
    ES2296311T3 (en) 2008-04-16
    DK0850646T3 (en) 2008-05-13
    AU718856B2 (en) 2000-04-20

    Similar Documents

    Publication Publication Date Title
    US20090041835A1 (en) Method of inhibiting leakage of drug encapsulated in liposomes
    FI79245B (en) FREQUENCY FRAGRANCE FOR UNILAMMED LIPOSOMERS.
    US4844904A (en) Liposome composition
    US8518437B2 (en) Lipid carrier compositions with enhanced blood stability
    KR100889139B1 (en) Irinotecan preparation
    ES2224299T3 (en) LIPOSOMAL DISPERSION OF ERYTHROYETIN.
    WO1990014074A1 (en) Improved liposomal formulations of nucleotides and nucleotide analogues
    JP2000086501A (en) Liposome formulation of human calcitonin
    CA2229892C (en) Liposome preparations of indolocarbazole derivatives
    US20050118249A1 (en) Lipid carrier compositions and methods for improved drug retention
    IT202000013042A1 (en) LIPOSOMAL SYSTEM WITH KILLER TNF-APOPTOSIS INDUCED LIGAND (KILLERTRAIL), PRO-APOPTOTIC-DIRECTING.
    EA010404B1 (en) Superloaded liposomes for drug delivery
    US9023384B2 (en) Liposome and method for injecting substance to cell using this liposome
    JPH06345663A (en) Liposome preparation containing vancomycin
    KR101971451B1 (en) Use of 2-hydroxyoleic acid incorporated in lipid vehicle
    EP2398463A1 (en) A method for amphiphilic drug loading in liposomes by ion gradient
    KR20090021065A (en) Liposome coated with protein to prolong circulation time in bloodstream and preparation method thereof
    JP4694776B2 (en) Fine particle composition or liposome preparation
    KR100768265B1 (en) Heparin coated liposomes to prolong circulation time in bloodstream and preparation method thereof
    Verma et al. Liposomes as carrier systems
    Naaz et al. International Journal of Modern Pharmaceutical Research
    JPH1171266A (en) Liposome preparation of xanthin derivative
    KR19980084791A (en) Treatment for iron deficiency anemia in which heme is trapped in liposomes and preparation method thereof
    MXPA99005478A (en) Complexes use of cationic liposomes and polideoxyribonucleotides as medicaments
    ITMI972748A1 (en) USE OF COMPLEXES BETWEEN CATIONIC LIPOSOMES AND POLYESOXYBONUCLEOTIDES AS MEDICATIONS

    Legal Events

    Date Code Title Description
    PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

    Free format text: ORIGINAL CODE: 0009012

    17P Request for examination filed

    Effective date: 19980312

    AK Designated contracting states

    Kind code of ref document: A1

    Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

    A4 Supplementary search report drawn up and despatched

    Effective date: 20050510

    RIN1 Information on inventor provided before grant (corrected)

    Inventor name: ITO, KUNIO

    Inventor name: YAMAUCHI, MASAHIRO

    Inventor name: KATO, YASUKI

    GRAP Despatch of communication of intention to grant a patent

    Free format text: ORIGINAL CODE: EPIDOSNIGR1

    GRAS Grant fee paid

    Free format text: ORIGINAL CODE: EPIDOSNIGR3

    GRAA (expected) grant

    Free format text: ORIGINAL CODE: 0009210

    AK Designated contracting states

    Kind code of ref document: B1

    Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

    REG Reference to a national code

    Ref country code: GB

    Ref legal event code: FG4D

    REG Reference to a national code

    Ref country code: SE

    Ref legal event code: TRGR

    REG Reference to a national code

    Ref country code: IE

    Ref legal event code: FG4D

    REG Reference to a national code

    Ref country code: CH

    Ref legal event code: EP

    REF Corresponds to:

    Ref document number: 69738416

    Country of ref document: DE

    Date of ref document: 20080207

    Kind code of ref document: P

    REG Reference to a national code

    Ref country code: PT

    Ref legal event code: SC4A

    Free format text: AVAILABILITY OF NATIONAL TRANSLATION

    Effective date: 20080319

    Ref country code: CH

    Ref legal event code: NV

    Representative=s name: BOVARD AG PATENTANWAELTE

    REG Reference to a national code

    Ref country code: GR

    Ref legal event code: EP

    Ref document number: 20080400693

    Country of ref document: GR

    REG Reference to a national code

    Ref country code: ES

    Ref legal event code: FG2A

    Ref document number: 2296311

    Country of ref document: ES

    Kind code of ref document: T3

    REG Reference to a national code

    Ref country code: DK

    Ref legal event code: T3

    PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

    Ref country code: ES

    Payment date: 20080620

    Year of fee payment: 12

    Ref country code: DK

    Payment date: 20080520

    Year of fee payment: 12

    Ref country code: CH

    Payment date: 20080613

    Year of fee payment: 12

    ET Fr: translation filed
    PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

    Ref country code: AT

    Payment date: 20080520

    Year of fee payment: 12

    PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

    Ref country code: FI

    Payment date: 20080604

    Year of fee payment: 12

    Ref country code: MC

    Payment date: 20080520

    Year of fee payment: 12

    Ref country code: PT

    Payment date: 20080516

    Year of fee payment: 12

    PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

    Ref country code: SE

    Payment date: 20080520

    Year of fee payment: 12

    Ref country code: NL

    Payment date: 20080521

    Year of fee payment: 12

    Ref country code: LU

    Payment date: 20080704

    Year of fee payment: 12

    Ref country code: IE

    Payment date: 20080520

    Year of fee payment: 12

    Ref country code: DE

    Payment date: 20080613

    Year of fee payment: 12

    PLBE No opposition filed within time limit

    Free format text: ORIGINAL CODE: 0009261

    STAA Information on the status of an ep patent application or granted ep patent

    Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

    PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

    Ref country code: IT

    Payment date: 20080626

    Year of fee payment: 12

    26N No opposition filed

    Effective date: 20080929

    PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

    Ref country code: GB

    Payment date: 20080605

    Year of fee payment: 12

    PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

    Ref country code: BE

    Payment date: 20080710

    Year of fee payment: 12

    PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

    Ref country code: GR

    Payment date: 20080527

    Year of fee payment: 12

    REG Reference to a national code

    Ref country code: PT

    Ref legal event code: MM4A

    Free format text: LAPSE DUE TO NON-PAYMENT OF FEES

    Effective date: 20091214

    BERE Be: lapsed

    Owner name: KYOWA HAKKO KOGYO CO., LTD.

    Effective date: 20090630

    PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

    Ref country code: MC

    Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

    Effective date: 20090630

    Ref country code: FI

    Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

    Effective date: 20090612

    REG Reference to a national code

    Ref country code: CH

    Ref legal event code: PL

    REG Reference to a national code

    Ref country code: DK

    Ref legal event code: EBP

    GBPC Gb: european patent ceased through non-payment of renewal fee

    Effective date: 20090612

    NLV4 Nl: lapsed or anulled due to non-payment of the annual fee

    Effective date: 20100101

    REG Reference to a national code

    Ref country code: FR

    Ref legal event code: ST

    Effective date: 20100226

    PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

    Ref country code: PT

    Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

    Effective date: 20091214

    PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

    Ref country code: LI

    Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

    Effective date: 20090630

    Ref country code: IE

    Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

    Effective date: 20090612

    Ref country code: FR

    Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

    Effective date: 20090630

    Ref country code: CH

    Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

    Effective date: 20090630

    PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

    Ref country code: FR

    Payment date: 20080515

    Year of fee payment: 12

    PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

    Ref country code: GB

    Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

    Effective date: 20090612

    PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

    Ref country code: DE

    Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

    Effective date: 20100101

    Ref country code: BE

    Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

    Effective date: 20090630

    Ref country code: AT

    Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

    Effective date: 20090612

    PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

    Ref country code: NL

    Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

    Effective date: 20100101

    Ref country code: DK

    Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

    Effective date: 20090630

    REG Reference to a national code

    Ref country code: ES

    Ref legal event code: FD2A

    Effective date: 20090613

    PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

    Ref country code: GR

    Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

    Effective date: 20100107

    Ref country code: ES

    Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

    Effective date: 20090613

    PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

    Ref country code: IT

    Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

    Effective date: 20090612

    PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

    Ref country code: LU

    Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

    Effective date: 20090612

    PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

    Ref country code: SE

    Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

    Effective date: 20090613